# Ossium Health

> Ossium Health recovers bone marrow from consented deceased organ donors, processes and cryopreserves it in an Indianapolis bank, and supplies matched cell products to transplant centers, researchers and surgeons. Its banked HPC, Marrow can give clinicians a ready donor option when a living donor search takes too long or a graft fails. The company also sells research and clinical-grade cells and viable bone matrix allografts.

- **Founded:** 2016
- **Headquarters:** San Francisco, United States
- **Founders:** Kevin Caldwell (CEO, President and Co-Founder), Erik Woods (Chief Science Officer, EVP and Co-Founder)
- **Products:** HPC, Marrow, HOPE Program, GMP Human Mesenchymal Stem Cells, GMP Human Selected CD34+ Cells, Research-use MSC and CD34+ cells
- **Notable:** First clinical-grade marrow donor banked in 2020., First reported successful HPC, Marrow transplant and engraftment at Henry Ford Health in June 2024., First pediatric Ossium marrow transplant at Riley Children’s Health in March 2026; the recipient’s second graft engrafted.

## Products & services

- **HPC, Marrow** — Cryopreserved whole bone marrow with hematopoietic progenitor cells recovered from deceased organ donor vertebral bodies.
- **HOPE Program** — Expanded access pathway for patients with urgent or unmet allogeneic bone marrow transplant needs; Ossium states eligible patients receive the marrow at no cost.
- **GMP Human Mesenchymal Stem Cells** — Clinical-grade mesenchymal stromal cells derived from organ donor vertebral marrow.
- **GMP Human Selected CD34+ Cells** — Aseptically selected and enriched hematopoietic cells for clinical development.
- **Research-use MSC and CD34+ cells** — Human cell products sold for laboratory research and therapy development.
- **OssiGraft and OssiGraft Prime** — Cryopreserved viable bone matrix allografts for repair, replacement and reconstruction of musculoskeletal defects.

## Achievements

- First clinical-grade marrow donor banked in 2020.
- First reported successful HPC, Marrow transplant and engraftment at Henry Ford Health in June 2024.
- First pediatric Ossium marrow transplant at Riley Children’s Health in March 2026; the recipient’s second graft engrafted.
- Ossium reported 28 patients treated with its organ donor marrow and neutrophil engraftment in every case by July 2026.
- Named to Forbes’s 2026 Next Billion-Dollar Startups list; the list is predictive recognition, not a $1 billion valuation.

## Latest updates

- **2026-07** — Named to Forbes’s 2026 Next Billion-Dollar Startups list; company reported 28 marrow recipients with neutrophil engraftment.
- **2026-07** — Disclosed first pediatric Ossium marrow transplant, performed in March at Riley Children’s Health after a prior living-donor graft failed.
- **2026-04** — Published organ donor hematopoietic stem cell engraftment research in Bone Marrow Transplantation.
- **2026-01** — Announced peer-reviewed Cytotherapy report on standardized cryopreservation and three early expanded access recipients.

## Links

- Website: https://ossiumhealth.com/
- LinkedIn: https://www.linkedin.com/company/ossiumhealth/
- Twitter/X: https://x.com/ossiumhealth
- Facebook: https://www.facebook.com/ossiumhealth/

---

Profile page: https://yespress.io/ossium-health
Published by YesPress — https://yespress.io
Last updated: 2026-09-29